Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, ...

Both LUNA and OPTIC were designed to assess a broad wet AMD population, including hard-to-treat patients with severe disease ...

Shares of Palatin Technologies, Inc. (PTN) gained 16% on Monday after the company announces completion of patient enrollment in phase ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

KEY POINTS A 72-year-old man presented to the emergency department with a 2-week history of hypotension, postural dizziness, and muscle weakness. He had a medical history of HIV, lipodystrophy, ...

Fortunately, the scan was negative. With the correct diagnosis in hand, we established that his condition was physiological — not psychological — and treated him with intravenous immunoglobulin and ...

A young teacher who suffers from severe asthma has spoken of how patients with the high-risk condition can be left on ...

If you are experiencing hair loss, find a dermatologist who will help you address the various aspects of hair thinning ...

LUNA is an ongoing double-masked, randomized Phase 2 trial. OPTIC is an ongoing, open-label, dose-ranging first-in-human ...

Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ...

ms10.hinet.net Objectives: To determine the efficacy of a two week and a four week course of oral steroids in the conservative treatment of carpal tunnel syndrome. Methods: 109 patients with carpal ...

Many people with sleep apnea benefit from oral devices that pull the lower jaw forward and hold it there, enlarging the ...